A study on the biological features of age-associated memory impairment (AAMI).

为了阐明年龄相关性记忆障碍（AAMI）的生物学特征，我们研究了正常对照老年人、AAMI受试者、早发型（AD）和晚发型（老年痴呆型阿尔茨海默病：SDAT）老年痴呆（ATD）患者以及血管性痴呆（VD）患者的稀释纯品胺滴眼液试验、血清α 1-抗chimotrypsine （α 1-ACT）浓度和载脂蛋白E ε 4等位基因（ApoE4）频率。采用严格的纳入和排除标准（NINCDS-ADRDA），我们招募了18例AD患者（63.1±5.8岁），26例SDAT患者（77.2±4.7岁），27例VD患者（75.0±6.7岁，0）。对于AAMI和非痴呆对照组(C)，分别入组24人（64.3±12.2 y.o）和21人（67.6±9.3 y.o）。结果与结论：1)在给予0.01% tropicamide的情况下，AAMI组（8.6±6.2%）与C组（7.8±5.5%）基本相等，且与AD-组（23.3±19.1%）和SDAT组（22.0±14.5%）差异有统计学意义（p<0.1）。然而，AD组和SDAT组之间没有显著差异。2) AAMI组血清α1-ACT值为278.10±36.3(μg/ml)， C组为259.6±32.7，AD组为303.7±87.8，SDAT组为324.2±82.6，VD组为314.7±72.5，仅SDAT组与C组差异有统计学意义（p<0.05）。3) SDAT组的ε4等位基因频率最高（40.0±40.8%），AAMI组的ε4等位基因频率（20.8±29.2%）介于C组（12.5±27.5%）和AD组（31.3±40.3%）之间。但各组间差异无统计学意义。我们的研究结果表明，AAMI可能不是一个独特的临床实体，而是由各种群体组成的，如完全正常的老年人和非常早期的阿尔茨海默型痴呆。

In order to clarify the biological features of age-associated memory impairment(AAMI) we investigated dilute tropicamide eye drop tests, serum α 1-antichimotrypsine (α 1-ACT) concentrations and apolipoprotein E epsilon 4 allele (ApoE4) frequencies in the normal control elderlys, AAMI subjects, the patients with Alzheimer type dementia(ATD) of early onset type(Alzheimer's disease : AD) and late onset type(senile dementia of Alzheimer's type : SDAT), and those with vascular dementia(VD). Using strict inclusion and exclusion criteria (NINCDS-ADRDA), we recruited 18 patients of AD (63.1±5.8 years old), 26 of SDAT(77.2±4.7 y.o.), 27 of VD(75.0±6.7 y,o.). Regarding AAMI and non-demented controls (C), 24(64.3±12.2 y.o.) and 21(67.6±9.3 y.o.) of persons were enrolled, respectively.Results and conclusion :1) In response to the administration of 0.01% of tropicamide, the value of AAMI group(8.6±6.2%) was nearly equal to that of C group(7.8±5.5%), which tended to be significant to AD-(23.3±19.1%) and SDAT groups(22.0±14.5%)(p<0.1). However, there was no significant differences to either AD or SDAT group.2) Serum α1-ACT values were 278.10±36.3(μg/ml) in AAMI, 259.6±32.7 in C, 303.7±87.8 in AD, 324.2±82.6 in SDAT, 314.7±72.5 in VD group, respectively, so that there was a significant difference only between SDAT and C group (p<0.05).3) The ε4 allele frequency showed the highest value in SDAT group(40.0±40.8%), and the value of AAMI(20.8±29.2%) was beween C(12.5±27.5%) and AD(31.3±40.3%). However, there was no significant difference among each group.Our results suggest that AAMI might not be a distinct clinical entity, but the one which consists of a variety of group such as entirely normal eldelys and a very early stage of Alzheimer Type Dementia.